Navigation Links
Cellectricon Files Patent Infringement Suit Against Fluxion Biosciences
Date:2/1/2010

GOTHENBURG, Sweden, February 1 /PRNewswire/ -- Cellectricon AB today announced that it has resumed its litigation against Fluxion Biosciences, Inc. Cellectricon filed the lawsuit in July 2009 in the United States District Court for the Northern District of California alleging infringement of several United States patents issued or licensed to Cellectricon for microfluidic technology used in Cellectricon's state-of-the-art ion channel drug screening solution, the Dynaflow(R)HT System. Cellectricon's U.S. Patents Nos. 7,390,650, 7,470,518 and 7,563,614 have been asserted in the litigation, as well as U.S. Patent No. 5,376,252, which is owned by Gyros, and licensed to Cellectricon.

Annelie Skafte Persson, Cellectricon's Chief Executive Officer, said, "Cellectricon invents and develops advanced cell-based microfluidic screening solutions for applications in drug discovery and basic research. Cellectricon has an extensive intellectual property portfolio with novel cell-based screening technologies based on fifteen years of world-renowned research. To ensure a fair return on our research and development efforts we must protect our intellectual property and we will take all necessary steps to prevent its unauthorized use."

Cellectricon's Chairman Lars-Eric Utterman added, "Cellectricon is a highly innovative company which has successfully launched several advanced screening systems on the life science market. Today's litigation is a strategic step to defend Cellectricon's intellectual property from being infringed."

About Cellectricon

Cellectricon AB, a Swedish biotech company, successfully provides groundbreaking products to the pharmaceutical and biotechnology industries. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfluidic technologies. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products address critical bottlenecks in the drug discovery process and have been adopted by top-reference customers, including nine of the top ten pharmaceutical companies. Cellectricon has developed two pioneering high throughput screening platforms in close collaboration with leaders in the pharmaceutical industry. Used in preclinical pharmaceutical development, the Cellaxess(R)HT System enables high throughput transfection for genomic screening and the Dynaflow(R)HT System greatly advances ion channel drug discovery.

    Contact Details:

    Annelie Skafte Persson, CEO
    E-mail: annelie.skafte.persson@cellectricon.com

    Susanne Fagerlund, VP Marketing & Communications
    E-mail: susanne.fagerlund@cellectricon.com

SOURCE Cellectricon AB


'/>"/>
SOURCE Cellectricon AB
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Share Issue Gives Cellectricon SEK 89 Million to Continue its Rapid Market Expansion
2. Cellectricon and AstraZeneca - Partners in New High Throughput Ion Channel Drug Discovery Technology
3. Cellectricon Receives Milestone Order for Cellaxess(R)HT, the Worlds First High Throughput RNAi Screening System
4. Cellectricon Partners With The Automation Partnership - Bringing Next Generation Ion Channel Screening System to Market.
5. Cellectricon and BioFocus DPI Advance High Throughput ion Channel Drug Discovery
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
8. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
9. Arrow International Files and Mails Definitive Proxy Materials
10. VaxGen Files 2006 Financial Statements and Provides Cash Update
11. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... 27, 2017 , ... The Council for Agricultural Science and ... Lusk, a consummate communicator who promotes agricultural science and technology in the public ... explains how innovation and growth in agriculture are critical for food security and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA official ... trials comes to Tampa, San Francisco and Boston in 2017. The 2016 ... organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., Cell ...
(Date:4/26/2017)... Pa. , April 26, 2017  Genisphere ... delivery platform, has signed a collaborative and sponsored ... Dr. Silvia Muro . The overall goal ... and pharmacodynamics of various 3DNA designs and formulations ... involve targeting diseases of the vasculature as well ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert G. Schwartz, ... proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined the practice ... , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert ...
Breaking Biology Technology:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
Breaking Biology News(10 mins):